eISSN: 1897-4309
ISSN: 1428-2526
Contemporary Oncology/Współczesna Onkologia
Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
3/2020
vol. 24
 
Share:
Share:
abstract:
Original paper

Survival and relative dose intensity of 5-fluorouracil, oxaliplatin and irinotecan in real-life treatment of metastatic colorectal cancer

Ilfad Blazevic
1
,
Willy Vaillant
2
,
Maud Basso
2
,
Karine Salignon
2

  1. Medical Oncology Department, University Cancer Institute Toulouse Oncopole, Toulouse, France
  2. Medical Oncology Department, Auch Hospital Center, Auch, France
Contemp Oncol (Pozn) 2020; 24 (3): 150–156
Online publish date: 2020/10/30
View full text Get citation
 
PlumX metrics:
Introduction
Combinations of 5-fluorouracil/leucovorin (5-FU/LV) with oxaliplatin (FOLFOX) or irinotecan (FOLFIRI) are part of standard treatments for metastatic colorectal cancer (mCRC). For these molecules, the impact of a low relative dose intensity (RDI) on survival is not sufficiently known in real-life.

Material and methods
Data were collected retrospectively from patients treated in our center for an unresectable mCRC with FOLFOX or FOLFIRI as a first-line treatment. To study the impact on progression-free survival (PFS) and overall survival (OS), patients were divided into high and low RDI according to the median RDI of 5-FU on one end, and the median RDI of oxaliplatin or irinotecan (OXA-IRI) on the other.

Results
In our population of 75 patients, the median age was 67.1 years and 77% of patients were treated with FOLFIRI. Patients with high RDI for OXA-IRI had better PFS compared to patients with low RDI (hazard ratio [HR], 0.58; p = 0.03). There was no statistically significant difference in PFS for patients with high RDI for 5-FU (HR, 0.66; p = 0.09). No difference was found in overall survival according to the RDI of OXA-IRI (HR, 0.72; p = 0.18) or 5-FU (HR, 0.77; p = 0.29). RDI had no significant impact on toxicities.

Conclusions
Our analysis suggests that a low RDI of oxaliplatin and irinotecan has a negative effect on PFS. RDI had no significant effect on OS in our cohort. The clinical benefit of maintaining high RDI in these patients appears low.

keywords:

colorectal cancer, relative dose intensity, chemotherapy, survival, real-life

Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.